Marstacimab - Pfizer

Drug Profile

Marstacimab - Pfizer

Alternative Names: PF-06741086; PF-6741086

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
  • Mechanism of Action Blood coagulation factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 06 Dec 2017 Pfizer plans a phase II trial for Haemophilia (SC) (NCT03363321) (EudraCT2017-001255-31)
  • 02 May 2017 PF 6741086 receives Orphan Drug status for Haemophilia A in USA before May 2017 (Pfizer pipeline, May 2017)
  • 08 Mar 2017 Phase-II clinical trials in Haemophilia in Chile (IV) (NCT02974855)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top